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Although natural opiates have been used for centuries, and semi-synthetic, and synthetic 
opiates have been used and abused for decades, these last few years have witnessed an 
incredible increase in opioid abuse and deaths due to overdose.  With this opioid crisis has 
come an increase in research into the mechanisms of analgesia, abuse, and addiction, 
interaction with other drugs, anatomical and imaging studies, as well as ethical discussions of 
opioid use and abuse.  This eBook, Current Topics in Opioid Research, presents 7 minireviews, 
2 hypotheses/perspectives, and 16 original research articles, from 13 different countries, and 
has articles that span the field of opioid research, gives insight into ongoing topics, and provides 
a basis for further study and potential reduction in severity of the opioid crisis. 
 
 
Hypothesis and Theory/Perspective Articles 
Drug Addiction: From Neuroscience to Ethics by  Farisco et al. presents a novel hypothesis 
concerning drug addiction. The authors suggest that in addition to well-described 
neuronal/neurochemical factors contributing to addictive dynamics, the socio-economic status 
also plays a causal role in drug addiction through epigenetic processes that require additional 
reward in the brain. This provides a strong base for a socio-political form of responsibility for 
preventing and managing addiction crisis. For this reason, the authors consider addiction to be 
a social disorder in addition to a medical and mental disorder. 
The Clinical Concept of Opioid Addiction Since 1877: Still Wanting After All These Years by  
Schütz et al. proposes a comprehensive theory of addiction that uses life and social sciences, 
dynamical and complex systems theory, and philosophical-phenomenological approaches to 
understand the full complexity of addiction while integrating neurobiological, psychological, and 
sociocultural aspects.  According to this theory, addiction can be viewed as a habit, induced by 
a network of mental, behavioral, and social processes, which not only shape the addict's 
perceptions and actions, but also cause one to self-maintain. 
Reward/Addiction 
 
In Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone 
and Buprenorphine, Noble and Marie discuss drug therapies for addiction treatment.  They 
discuss the benefits and detriments of the two mu opioid agonists, with a brief discussion of 
drug characteristics leading to these properties.  They also discuss the use of the opioid 
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antagonist naltrexone and potential leads towards next generation medications, including the 
use of biased agonists, NOP receptor agonists, or potentially enkephalin degradation inhibitors.   
In Enkephalin as a Pivotal Player in Neuroadaptations Related to Psychostimulant Addiction, 
Mongi-Bragato et al., address changes in enkephalin levels in the mesocorticolimbic reward 
circuity due to administration of psychostimulants. The authors discuss how these changes 
affect signaling of mu and delta opioid receptors and the importance of receptor activation with 
respect to cocaine and amphetamine-induced behavioral sensitization, conditioned place 
preference, and self-administration.  
Previously, Li et al., had demonstrated that activation of Trx-1, an important redox regulating 
protein, could protect mice from the rewarding effects of morphine. In Overexpression of 
Thioredoxin-1 Blocks Morphine-Induced Conditioned Place Preference Through Regulating the 
Interaction of γ-Aminobutyric Acid and Dopamine Systems, these authors demonstrate that 
morphine-induced conditioned place preference (CPP) was blocked in Trx-1 overexpressing 
transgenic mice.  Furthermore, Trx-1 expression was induced by morphine in the ventral 
tegmental area (VTA) and nucleus accumbens (NAc) in wild-type mice. The level of dopamine, 
expression of tyrosine hydroxylase, and D1 dopamine receptor as well as levels of GABA and 
GABAB-Rs were altered by chronic morphine.  Therefore, Trx-1 may play a role in blocking CPP 
induced by morphine through regulating the expressions of D1, TH, and GABABR in the VTA 
and NAc. 
Two papers described effects on drug abuse models subsequent to activation of NOP 
receptors, the fourth member of the opioid receptor family. In NOP receptor agonist Ro 64-6198 
decreases escalation of cocaine self-administration in rats genetically selected for alcohol 
preference, Li et al. examine the effect of NOP receptor agonist Ro 64-6198 on alcohol self-
administration in Marchigian Sardinian alcohol-preferring (msP) rats that have an upregulated 
NOP receptor system and in Wistar control rats. Ro 64-6198 was better able to attenuate 
cocaine self-administration in msP than in Wistar rats. 
In The Nociceptin Receptor (NOP) Agonist AT-312 Blocks Acquisition of Morphine- and 
Cocaine-Induced Conditioned Place Preference in Mice,  Zaveri et al discuss the actions of AT-
312, a selective NOP agonist, on morphine and cocaine CPP. AT-312 blocked acquisition of 
both morphine and cocaine, as well as locomotor stimulation in wild type but not NOP receptor 
knockout mice. These results demonstrate that NOP agonists may have potential as 
pharmacotherapy for opioid and psychostimulant addiction or for treating polydrug addiction. 
Three papers focused on the relationship between opiates and alcohol abuse.  In Binge-Like 
Exposure to Ethanol Enhances Morphine's Anti-nociception in B6 Mice, Chang et al hypothesize 
that binge drinking potentiates onset and progression of opioid use disorder (OUD).  To 
examine this, the authors examined and found an increase inflammatory cytokines and mu 
receptor mRNA in the striatum after binge ethanol drinking. This corresponded with an increase 
in potency of morphine at 3 mg/kg in the hotplate test.  Such effect might initiate the onset and 
progression of OUDs. 
Granholm et al., described the effects of ethanol exposure on the level of opioid peptides in 
Episodic Ethanol Exposure in Adolescent Rats Causes Residual Alterations in Endogenous 
Opioid Peptides.  To mimic binge drinking in adolescents, the authors administered ethanol to 
rats three days per week from weeks 4-9.  Beta-endorphin, dynorphin B and Met-enkephalin-
Arg6Phe7 (MEAP) were then analyzed 2 h and 3 weeks after the final ethanol administration.  
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Changes were observed for each peptide in selected brain regions. These alterations in opioid 
networks after adolescent ethanol exposure could explain, in part, the increased risk for high 
ethanol consumption later in life. 
In Critical Role for Gi/o-Protein Activity in the Dorsal Striatum in the Reduction of Voluntary 
Alcohol Intake in C57Bl/6 Mice, Robins et al. explore the hypothesis that dorsal striatal Gi/o-
protein activation is sufficient to reduce voluntary alcohol intake. The authors examined this 
hypothesis in two ways.  In one set of experiments, they expressed the inhibitory, Gi/o-coupled, 
M4 DREADD in the dorsal striatum. In these animals, receptor activation with CNO reduced 
consumption of 10% ethanol in a two-bottle choice paradigm. In other experiments, delta opioid 
receptor activation with the Gi/o biased agonist TAN-67 reduced alcohol consumption in wild 
type and b-arrestin-2 KO animals, while activation with the β-arrestin-2 biased agonist SNC80 
increased alcohol intake in wild type but decreased intake in b-arrestin-2 KO animals.  These 
results suggest that activation of Gi/o coupled receptors in the striatum, with biased agonists, 
could be a mechanism for treating alcohol use disorder. 
In CB1 Agonism Alters Addiction-Related Behaviors in Mice Lacking Mu or Delta Opioid 
Receptors,  Roeckel et al. investigate the interaction between opioid and cannabinoid CB1 
receptors with respect to pain, withdrawal, anxiety and depression using the selective CB1 
agonist ACEA, as well as mu and delta opioid receptor KO mice. The authors demonstrated that 
ACEA had no antinociceptive activity of its own in the warm water tail withdrawal test.  Naloxone 
was able to precipitate withdrawal from chronic ACEA in mice of all genotypes. Anxiety-like 
behavior was independent of genotype and ACEA treatment, but a pro-depressive effect of 
ACEA was absent in mu KO mice.  These studies indicate an interaction between opioid and 
CB1 receptors in withdrawal and depression. 
 
Butelman et al. examine opioid-dependent patients to determine if other drug use was a 
predictor of ultimate opioid dependence.  In Non-medical Cannabis Self-Exposure as a 
Dimensional Predictor of Opioid Dependence Diagnosis: A Propensity Score Matched Analysis, 
the authors used an outpatient observational study to examine age of onset of heaviest use of 
cannabis, cocaine, and alcohol and how that correlated with the onset of opioid dependence.  
They concluded that the maximal self-exposure to cannabis and cocaine, but not to alcohol, was 
greater in volunteers with opioid dependence and that increasing self-exposure to cannabis and 
cocaine, but not alcohol, was a positive predictor of opioid dependence. 
 
Pain 
Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic, by Severino 
et al., discusses the history behind the current opioid epidemic then goes on to review potential 
methods for treatment of pain without off-target effects. To this end, the authors discuss the 
potential for ligand bias and bifunctional opioid agonists as potential methods of reducing side 
effects and also outline how the pharmacokinetic profile of opioids contribute to their potential 
for addiction and abuse. 
In The Contribution of the Descending Pain Modulatory Pathway in Opioid Tolerance, Lueptow 
et al. review mechanisms that underlie opioid tolerance development, concentrating on the 
descending PAG-RVM-spinal cord pain pathway. The authors describe how tolerance in the 
PAG is mediated by mu receptor uncoupling from downstream G-protein mediated signaling. 
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Other experiments describe the relationship between tolerance development and glial 
activation; particularly the role of TLR4 in that relationship also is discussed. 
In Cutting-edge search for safer opioid pain relief: retrospective review of salvinorin A and its 
analogs, Zjawiony et al review the development of salvinorin A analogs from the perspective of 
a medicinal chemist.  Salvinorin A, a natural product purified from Salvia divinorum, is a 
selective and high affinity kappa agonist.  Salvia is currently used as a recreational drug since it 
alters consciousness, but like kappa drugs is often dysphoric. Nevertheless, it has been used as 
a template for drug discovery leading to the production of many kappa and mu selective 
agonists.  In particular, many analogs appear to have ligand bias, which might be useful in 
developing drugs with lower abuse potential. 
In Advances in Achieving Opioid Analgesia Without Side Effects, Machelska and Celik review 
emerging opioid-based strategies to develop effective analgesics with reduced side effect 
profile.  The novel concepts discussed include biased agonism, peripherally active compounds, 
heteromeric compounds, receptor splice variants, and use of endogenous opioids by inhibiting 
degradation or enhancing production. Compounds in clinical trials and undergoing preclinical 
studies are identified. 
Zhang et al, examined the involvement of NOP receptors on a PTSD model in male and female 
rats in Sex Differences in Nociceptin/Orphanin FQ Peptide Receptor-Mediated Pain and Anxiety 
Symptoms in a Preclinical Model of Post-traumatic Stress. Interestingly, male NOP receptor KO 
rats did not develop single prolonged stress-induced allodynia and thermal hypersensitivity, 
while female NOP receptor KO rats exhibited tactile allodynia and thermal hypersensitivity to the 
same extent as WT rats.  These experiments demonstrate the distinct role that the NOP 
receptor system plays in males and females after exposure to sustained stress. 
Philip Stötzner, et al., in Mu-Opioid Receptor Agonist Induces Kir3 Currents in Mouse Peripheral 
Sensory Neurons – Effects of Nerve Injury explore the activity of mu receptors in the DRG to 
examine the potential of peripherally active mu agonists as analgesics with greatly reduced side 
effects.  Receptor activity was determined by measuring activity of the G protein-coupled 
inwardly rectifying potassium channels, Kir3 in the DRG of naïve and chronic pain (chronic 
constriction injury) mice. The authors determined that the mu agonist DAMGO could activate 
Kir3 currents and the percentage of mu-containing DRG neurons was equivalent in naïve and 
CCI mice.  
Pain/Novel Ligands 
In In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent 
Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice,  Lattanzi 
et al. discuss in vitro and in vivo properties of this novel compound (POMO).  POMO is 14-O-
phenylpropyl substituted analog of the mu-opioid agonist 14-O-methyloxymorphone (14-OMO). 
POMO has subnanomolar affinity at mu, delta, and kappa receptors and is a full agonist at mu 
and delta.  Importantly, it is a very potent analgesic, with an ED50 of 0.7 nmol/kg, 9000 times 
more potent than morphine.  Despite the extremely potent antinociceptive activity, it has 
reduced inhibition of gut transport, suggesting a greater therapeutic window.   
Kumar et al, performed a structure activity relationship study of  oxymorphinone analogs in 
Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-
cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and 
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Opioid Receptor Profile.  Affinity and in vitro efficacy were determined at mu, delta, kappa, and 
NOP receptors. All compounds were partial agonists at each receptor, and SAR results were 
consistent with molecular modeling predictions that a binding site within the NOP receptor could 
be accessed by an appropriate 14β side chain.  This resulted in compounds with much higher 
affinity at NOP receptors than the parent compound naltrexone. 
Mu Receptor 
Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo by Ugur et al., 
reviews the evidence for heteromers of the mu receptor, and discusses how heteromers affect 
mu opioid receptor signaling, trafficking and subsequent behavioral responses. The authors 
describe how selective targeting of heteromers to modulate mu opioid receptor activity has 
attracted significant interest as a method for developing novel innovative therapeutics. 
In Microglia Express Mu Opioid Receptor: Insights From Transcriptomics and Fluorescent 
Reporter Mice, Maduna et al examine microglia for the presence of the mu receptor. The 
reasoning behind these experiments were the observations that microglia appear to mediate 
certain adverse effects of opiates including analgesic tolerance and opioid-induced 
hyperalgesia.  Using transcriptomic databases from both mice and humans, as well as imaging 
of newly created Cx3cr1l-eGFP-MOR-mCherry mice, the mu receptor was found in the vast 
majority of mouse and human microglia datasets.  Furthermore, mu receptors could be found in 
roughly 40% of microglia in both brain and spinal cord. These results are consistent with 
functional studies showing the actions of mu receptor agonists on microglia. 
In Oxycodone Self-Administration Induces Alterations in Expression of Integrin, Semaphorin and 
Ephrin Genes in the Mouse Striatum, Yuferov et al examined the effect of chronic oxycodone 
treatment on molecules that affect axon guidance including integrin, semaphorin, and ephrin 
gene families.  It was the author’s hypothesis that opioid-induced changes in axon-target 
connections and synaptogenesis may be implicated in the behaviors associated with opiate 
addiction. Chronic oxycodone caused either an increase or decrease in the majority of the 38 
known genes in these gene families. The relationship between expression of these genes and 
specific behaviors is under investigation. 
Mu Receptor Imaging 
In Deformation-based Morphometry MRI Reveals Brain Structural Modifications in Living Mu 
Opioid Receptor Knockout Mice,  Nasseef et al used a structural MRI approach to determine 
whether volumetric alterations also occur in MOR KO mice.  The authors measured 
deformation-based morphometry (DBM) for each voxel in subjects from MOR KO and control 
groups. They found volumetric changes, both contractions and expansions in various brain 
regions, mainly in mu receptor-enriched regions and across reward/aversion centers. Some 
volumetric changes were in regions that showed functional connectivity changes identified in a 
previous Rs-fMRI study, suggesting a possible function-structure relationship in mu KO-related 
brain alternations. These functional and structural MRI studies disclose whole-brain level 
mechanisms that likely drive MOR-controlled behaviors. 
Sasaki et al demonstrated changes in tissue volume in the periaqueductal gray matter (PAG) 
using magnetic resonance imaging voxel-based morphometry. In Larger Numbers of Glial and 
Neuronal Cells in the Periaqueductal Gray Matter of μ-Opioid Receptor Knockout Mice. These 
authors used immunohistochemistry to measure numbers of microglia, astrocytes, and neurons 
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in four subregions of the PAG.  They found larger numbers of each of these cell types in mu KO 
compared to wild type mice, suggesting that these alterations might account for the 
hyperalgesic state in mu KO mice.  
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